Cipla targets $1 bn US revenue in FY27
Cipla
aims to achieve $1 billion sales in the US by the next fiscal year, driven by the products it has lined up for launch which the Indian drug maker expects will more than compensate for the imminent patent expiry and price erosion on cancer drug Revlimid.
'We believe our pipeline should get us closer to the target (of $1 billion) or surpass that by FY27, depending on the launch timing,' managing director and global chief executive Umang Vohra said over an investor call on Friday.
Explore courses from Top Institutes in
Please select course:
Select a Course Category
Management
others
Finance
Technology
MBA
Degree
PGDM
Cybersecurity
Project Management
Data Science
CXO
Digital Marketing
Design Thinking
Product Management
healthcare
Operations Management
Data Science
Leadership
Data Analytics
Public Policy
MCA
Others
Artificial Intelligence
Skills you'll gain:
Duration:
10 Months
IIM Kozhikode
CERT-IIMK GMPBE India
Starts on
undefined
Get Details
Skills you'll gain:
Duration:
11 Months
IIM Kozhikode
CERT-IIMK General Management Programme India
Starts on
undefined
Get Details
Skills you'll gain:
Duration:
9 Months
IIM Calcutta
CERT-IIMC APSPM India
Starts on
undefined
Get Details
'We have plans for all our launches that are coming in to make up for the revenue losses for Revlimid and that will happen in the short to medium term,' he added. The US remains a very attractive market for Cipla. 'We see it as a growth market over the next 3-5 years,' he said.
A generic version of Revlimid (lenalidomide) is one of Cipla's top-selling products in the US. As part of an out of court settlement,
Cipla
manufactures and markets the drug in the US.
Analysts said the expiry of the drug's patent is expected to significantly impact Cipla through a reduction in revenue and potential margin pressure.
Cipla has a robust pipeline for the US business with respiratory generic Advair closer to commercialisation and is also preparing for launch of generic Symbicort and a couple of inhalation products. It also plans to launch 2–3 peptide assets in FY26.
Timely monetisation of these launches remains critical for the company to offset the lenalidomide generic sales erosion, according to a report by broking firm IIFL.
Vohra sees the respiratory segment and new product launches lined up in the category to be the biggest opportunity for Cipla in the next 12 months. 'We have 3-4 launches coming up for the US alone, we have several coming up for emerging markets and several for India,' he told ET.
About potential US tariffs on the pharma sector, Vohra said he does not see it having a 'debilitating effect'. There will be an impact, but it will not derail the business, he said.
The company on Friday reported a 10% year-on-year increase in consolidated net profit to Rs 1,298 crore for the first quarter ended June. Revenue rose 4% to Rs 6,957 crore and Ebitda was 25.6% of the revenue, the company stated in a filing with stock exchanges.
Its India business delivered growth of 6% year-on-year, topping Rs 3,000 crore for the first time ever in a quarter, contributing 44% to the total revenue.
Revenue from North America was $226 million (about Rs 1,955 crore) supported by traction in differentiated assets. It launched two generic oncology products in the US in the past quarter: nano paclitaxel vials and nilotinib capsules.
'This performance builds on a strong prior year-on-year quarter where we achieved our highest ever US generics revenue,' said Vohra.
Meanwhile, the company has signed an agreement to launch its first biosimilar product in the US that is expected in Q2 FY26.
'We will in-license a few assets through partnerships in the near term and maybe launch our own biosimilar assets around 2029-2030,' Vohra said.
The company is betting big on GLP-1, which controls sugar levels and appetite, and sees it as a 'significant growth driver for its business.'
'For us the entire GLP 1 category is important rather than looking at individual categories within that. It will shape up in a manner depending on pipeline assets,' said Vohra. Cipla aims to be among the first wave of launchers for the drugs. The company plans to have a hybrid strategy including having its own products as well as through partnerships.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mint
19 minutes ago
- Mint
Tiger Global-backed Progcap expands beyond lending, pilots tech platform for MSMEs
Progcap, a fintech company focused on small businesses, is setting up a new vertical that will digitise their supply chains and offer them on-the-spot credit. It is building a full-stack software-as-a-service (SaaS) platform for brands, distributors and retailers, expanding from pure-play lending into embedded finance as a second revenue source, co-founders Pallavi Shrivastava and Himanshu Chandra told Mint. 'Large corporates have access to platforms like Salesforce but the actual sales process on the ground was still very analog. If you can place the order on the spot and initiate the payment process immediately, it leads to better conversion. Smaller brands and distributors lacked access to such tech," said Chandra. Progcap's new vertical will digitise this supply chain end-to-end and is already live with over 40 companies. Progcap plans to scale up embedded credit on this platform. Embedded credit means getting a loan right where you're buying or selling something, without going to a bank. 'We want to be the operating system for these brand-distributor-retailer ecosystems," said Shrivastava. This comes as Indian businesses such as Zepto's Atom, Big Basket's BB Matrix and InsuranceDekho's Heph launch their SaaS verticals to diversify revenue streams. Currently, Progcap's SaaS vertical offers credit only through Progfin, its non-banking finance company. The company aims to onboard over 200 brands and will open the SaaS platform to other banks and financial institutions by year-end, the founders said. Revenue contribution from the SaaS and embedded credit vertical is expected to be 10-15% over the next two to three years as lending will continue to be the main business. 'It is significantly reducing our customer acquisition cost. If the transaction is initiated on our platform, there's a high likelihood that we'll also be chosen to finance it," said Chandra. He added that it is helping reduce feet-on-the-street sales teams. 'Sales teams of our partner brands essentially became our onboarding channels, and we didn't need to send field teams," said Chandra. Automating processes This comes as companies actively think of further automating their processes and reducing costs to become leaner and turn profitable. Progcap's revenue from operations almost doubled to ₹139 crore in FY24 from ₹71 crore in FY23, while it managed to narrow its loss to ₹46 crore from ₹49 crore. The company is yet to file its FY25 financials. Founded in 2017 by Srivastava and Chandra, the financial service company, last valued at over $600 million, gets 95% of its revenue from lending to micro and small businesses. Within the SaaS platform, direct monetisation will come from subscription-based fees charged to brands and distributors. In addition, the new vertical opens up international expansion possibilities for Progcap. 'Lending is heavily regulated and requires deep market understanding. SaaS, however, is globally scalable," said Chandra. 'Some large brands are already asking us if we can deploy this in Bangladesh or Indonesia. So, once we prove the product in India, we will consider expanding it internationally." Though still at an early revenue stage, the SaaS platform is expected to be spun off as a separate entity company in two to three years as Progcomm, said Shrivastava. Co-founder Chandra leads this vertical fulltime, she added. Funding in the works Progcap is also preparing to raise a fresh round of equity capital to fund growth. The new round will include a secondary component to provide partial exits to early investors, the founders said. 'We haven't hit the market yet," said Shrivastava. 'But we're looking at capital to expand geographically, grow the team, scale the lending book, and double down on SaaS plus embedded credit. A portion may go into secured lending pilots as well." The company has been diversifying revenue outside of unsecured lending, an area that's come under greater scrutiny of the banking regulator. So far, Progcap has raised about $110 million across four funding rounds from marquee investors such as Tiger Global, Sequoia Capital India and Google. 'The valuation will depend on timing and market conditions. We're not chasing vanity milestones," Shrivastava said. Progcap aims to grow its assets under management to ₹3,000 crore by the end of FY26, riding on strong demand for formalised credit in India's underserved micro, small and medium enterprise sector.
Indian Express
21 minutes ago
- Indian Express
With Aug 1 deadline looming, India's faces a trade predicament: to accommodate Trump's hardball tactics while maintaining tariff advantage
With less than a couple of days left for the August 1 deadline that the Donald Trump administration set itself to thrash out deals with its trading partners, the American President said he is planning tariffs for 'the rest of the world' at 'somewhere in the 15 to 20 per cent range'. That would mean a significant increase on the 10 per cent 'baseline' tariff that currently applies to most trading partners. India's talks with the US for an interim deal are in a limbo of sorts, given the lack of a significant breakthrough so far. As things stand, three things are clear: the US is pushing for zero duty access to the Indian markets, like the deals it has got with Vietnam and Indonesia. That would, however, be a tough demand for India to accommodate. Secondly, from its perspective, New Delhi is pushing for a headline tariff number of around 15 per cent for its goods going into the US, like what was offered by the Americans to the EU and Japan, with the comparative tariff advantage starting to diminish if the tariff starts to go over figure and inch up closer towards the 20 per cent mark, or even higher. Also, going by the deals signed by the US so far, the tariff scenario for each country seems to be dependent on multiple external factors as well. This includes investment commitments and promises on directional shifts in trade in goods that America is keen to peddle. The Trump administration is learnt to be pushing for India to commit to specific purchases and investments, of the sort that it got the EU and Japan to sign up for. The commitment for purchases should not be a big issue for India, given that Trump is ostensibly focused on extracting a big figure that runs into billions of dollars, without even bothering to specify the time-frame for achieving these targets. The full texts of the deals for both Japan and the EU are not out, and are unlikely to be out anytime soon. India has comminated its openness to purchasing three big-ticket items from America: defence equipment, natural gas imports and nuclear reactors. Cobbling together a big number might not be a difficult task. Agri and dairy, two contentious issues, are likely off the table for now, which is positive for New Delhi. Also, with the UK deals, India has shown a willingness to be flexible on segments such as opening up public procurement. That gives some headroom for Indian negotiators for the final push. Indications are that a sixth round of talks between the two negotiating teams is expected to take discussions forward mid next month. What could be instructive is the limited takeaway from the Japan deal: how the Japanese negotiators managed to upstage their American counterparts by getting an immensely favourable deal on automobiles, even as they dangled the agri market access concessions and Tokyo's investment pledges as distraction the entire time. While India's trade deal with the US is likely to be less focused on sectors and more focused on the headline number unlike its UK deal, New Delhi is likely to push for market access in labour-intensive sectors, while trying to ensure a significant tariff differential compared to its Asian peers. Now, if the final headline tariff offered to India by Washington DC is between 10 per cent and 15 per cent, the tariff points offered to the UK and Japan, New Delhi should have reasons to be satisfied. The advantage starts to taper off once the tariff goes over 15 per cent and inches up closer to 20 per cent, as was offered by the US to Vietnam. A transshipment clause, of the kind slapped on Vietnam, could be a problem for India, given that a lot of Indian exports have inputs and intermediate goods in sectors such as pharma, engineering goods and electronics coming in from outside, including China. Also, clarity on the final American duty offer on China is a number that negotiators will be looking at, given the implicit assumption in New Delhi that the Trump administration will maintain a tariff differential. For Indian negotiators, other tariffs, over and above the baseline tariffs and the sectoral ones on steel and aluminum, is an added complication. Sectoral tariffs such as the 50 per cent on steel, aluminum and copper are already impacting India's exports to the US, and Trump's threat of steep tariffs on BRICS countries over them buying Russian oil is a looming concern. Will that be neutralised in the agreement is a question. Another question for New Delhi is: in the absence of any kind of interim deal, should it brace for an eventuality where there may not just be 26 per cent reciprocal tariffs, plus a 10 per cent additional BRICS tariff as well? That's perhaps the absolute worst case scenario, till an agreement is achieved. A tariff in the 15-20 per cent range would mean India still compares reasonably well with Indonesia (19 per cent), Vietnam (20-40 per cent) and has an advantage against China (30-34 per cent) and Bangladesh (35 per cent), without the additional BRICS tariff being factored in. Meanwhile, as the uncertainty continues, India's exporters are struggling to navigate the way forward because the buyers are not clear as to what the final tariff is going to be, and are consequently holding back on placing orders. The higher tariffs that the US has imposed on China means a number of Chinese manufacturers are now rerouting shipments to Europe at throwaway prices, which is impacting India's exports to the EU as well. India, like other countries, had frontloaded a lot of shipments ahead of the reciprocal tariff deadline for the ongoing Spring-Summer season, but a big question mark looms over the Fall-Winter season spanning October-March. Once the official level discussions wrap up by mid next month, there is a sense that a final call on the deal could come down to a conversation between the two leaders, Prime Minister Narendra Modi and President Trump. This is especially so since the American President is the trade negotiator-in-chief in this entire tariff rationalisation exercise. A firm commitment from India to purchasing American defence equipment, natural gas and nuclear reactors, alongside some kind of guidance on India cutting its purchases of fossil fuels from Russia could be part of the final offer from New Delhi. Trump needs to be convinced of a deal that he can hard sell as a victory to his base. The best case scenario for India would be to get a deal of some sort now, and then build on that in the future negotiations that could run into 2026. For Trump, another growing consideration could be the fact that higher tariffs are making it nearly certain that American households will pay higher prices for the everyday goods that are made overseas and imported into the US. Inflation is a looming reality. A Yale estimate from July 23 found that the tariffs will result in as much as $2,700 in 'lost annual income' per household, though the taxes collected would potentially help narrow the long-running federal deficit. The tariffs that have kicked in so far are bringing in some money into the US Treasury, with tariff revenue pegged at $27.2 billion in June and $22.8 billion in May, according to the Treasury Department's monthly statements, a sharp increase from earlier years. Anil Sasi is National Business Editor with the Indian Express and writes on business and finance issues. He has worked with The Hindu Business Line and Business Standard and is an alumnus of Delhi University. ... Read More
Indian Express
21 minutes ago
- Indian Express
Maharashtra cooperative banks' agricultural NPA rise drastically; poll promises of farm loan waiver blamed
Cooperative banks in Maharashtra have seen a sudden rise in non-performing assets (NPA) related to the agriculture sector. This rise in such loans defaulted by borrowers is a result of a combination of factors, including loan-waiver promises made before the Assembly polls and public sector banks failing to lend to farmers. This rise in NPA in the cooperative sector comes at a time when the central government has taken major reforms and is refinancing the sector. As of March 31, 2025, agri NPA in the cooperative sector stood at 24.11 per cent – a steep rise from the 17,85 per cent for the quarter ending December 31, 2024. The total NPA amount of cooperative banks stood at Rs 8,214 crore as of March-end, compared to Rs 7,739 crore in December-end. Across Maharashtra, agricultural NPA stood at Rs 31,253 crores – a rise from Rs 31.059 crore in December-end. The sector has seen a rise in NPA percentage from 11.80 per cent by December-end to 11.97 per cent by March-end. If cooperative banks see a rise in farmers defaulting, public sector banks have a completely different picture. The agricultural NPA of these banks went down from Rs 18,940 crore at the end of December to Rs 18,764 crore by the end of March. Agricultural NPA in these banks by March-end was at 16.73 per cent, down from 17.08 per cent. All figures are from the agenda of a meeting of the State Level Bankers Committee in India (SLBC) dated May 19, 2025. The lending structure of cooperative banks is different from that of public-sector banks. While public-sector banks treat each farmer as a single unit for lending, cooperative banks mostly lend through village-level Primary Agricultural Cooperative Societies (PACS). The PACS sends out the total requirement of loans to the district-level banks and disburse loans to farmers at the individual level. While there can be a host of reasons for the rise in cooperative banks' NPA, Anil Ghanwant, leader of Shetkari Sanghatana, said the pre-poll promise of a complete loan waiver, which continued to resonate even after the elections, is one of them. 'What we need to understand is that the cooperative banking structure has a strong political bias to it. Most political leaders are on the boards of cooperative banks. So when it comes to repayment, there is an indirect go-slow order on the bank officials,' he said. But Vijay Jawandhiya, another farm leader, had a very different take. According to him, the NPA in the cooperative banks rose mostly because the sector lends more proactively than public-sector banks. 'We have to understand that the public-sector banks are wary of lending to farmers. Thus, the increase in NPA is a reflection of lower lending by them,' he said. Partha Sarathi Biwas is an Assistant Editor with The Indian Express with 10+ years of experience in reporting on Agriculture, Commodities and Developmental issues. He has been with The Indian Express since 2011 and earlier worked with DNA. Partha's report about Farmers Producer Companies (FPC) as well long pieces on various agricultural issues have been cited by various academic publications including those published by the Government of India. He is often invited as a visiting faculty to various schools of journalism to talk about development journalism and rural reporting. In his spare time Partha trains for marathons and has participated in multiple marathons and half marathons. ... Read More
